White blood cell count predicts all-cause mortality in patients with suspected peripheral arterial disease.
OBJECTIVE
We investigated whether markers of inflammation-white blood cell (WBC) count, C-reactive protein (CRP), and lipoprotein-associated phospholipase A2-are associated with mortality in patients referred for noninvasive lower-extremity arterial evaluation.


METHODS
Participants (n = 242, mean age 68 years, 54% men) were followed for a median of 71 months. Ankle-brachial index (ABI), WBC count, plasma CRP, and lipoprotein-associated phospholipase A2 were measured at the start of the study. Factors associated with all-cause mortality were identified using Cox proportional hazards.


RESULTS
During the follow-up period, 56 patients (25%) died. Factors associated with higher mortality were greater age, history of coronary artery disease/cerebrovascular disease, lower ABI, higher serum creatinine, and higher WBC count/plasma CRP. In stepwise multivariable regression analysis, ABI, serum creatinine, WBC count, and CRP were associated significantly with mortality. Patients in the top tertile of WBC count and CRP level had a relative risk of mortality of 3.37 (confidence interval [CI], 1.56-7.27) and 2.12 (CI, 0.97-4.62), respectively. However, only the WBC count contributed incrementally to prediction of mortality. Inferences were similar when analyses were limited to patients with peripheral arterial disease (ABI<0.9, n = 114).


CONCLUSIONS
WBC count, but not plasma CRP level, provides incremental information about the risk of death in patients referred for lower-extremity arterial evaluation and in the subset of these patients with peripheral arterial disease.
Arain
Faisal A
FA
The Gonda Vascular Center and Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn. 55905, USA. arain.faisal@mayo.edu
Khaleghi
Mahyar
M
Bailey
Kent R
KR
Lahr
Brian D
BD
Rooke
Thom W
TW
Kullo
Iftikhar J
IJ
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis*; D002423:Cause of Death; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D016491:Peripheral Vascular Diseases / Q000097:blood* / Q000401:mortality*; D011237:Predictive Value of Tests; D011379:Prognosis
D002097:C-Reactive Protein; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase
Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):658-70
15662026
Circulation. 2004 Jul 13;110(2):227-39
15249516
Circulation. 2002 Feb 19;105(7):800-3
11854118
Vasc Med. 2004 May;9(3):171-6
15675180
Stroke. 2004 May;35(5):1147-52
15017013
JAMA. 2001 May 16;285(19):2481-5
11368701
Nature. 2002 Dec 19-26;420(6917):868-74
12490960
Am J Cardiol. 2005 Nov 15;96(10):1374-8
16275181
Circulation. 2002 Mar 5;105(9):1135-43
11877368
Arch Intern Med. 2004 Feb 23;164(4):433-9
14980995
Ann Intern Med. 2008 Jan 15;148(2):85-93
18195333
Am J Cardiol. 2005 Dec 1;96(11):1579-83
16310445
Int J Cardiol. 2006 Jan 26;106(3):291-7
16337036
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
17569110
J Vasc Surg. 2007 Sep;46(3):500-6
17681710
Mayo Clin Proc. 2007 Jun;82(6):709-16
17550751
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1966-71
15976323
J Am Coll Cardiol. 2004 Nov 16;44(10):1945-56
15542275
Arch Intern Med. 2005 Nov 28;165(21):2454-6
16314539
J Vasc Surg. 2005 Apr;41(4):610-7
15874924
JAMA. 2007 Mar 21;297(11):1197-206
17374814
Circulation. 2007 Feb 6;115(5):e69-171
17194875
N Engl J Med. 1992 Feb 6;326(6):381-6
1729621
J Vasc Surg. 2005 Aug;42(2):243-51
16102622
JAMA. 2001 Sep 19;286(11):1317-24
11560536
N Engl J Med. 2008 Sep 4;359(10):1018-26
18768945
N Engl J Med. 2006 Jul 20;355(3):251-9
16855265
Mayo Clin Proc. 2007 Feb;82(2):159-65
17290721